Spark Kidney, Inc.

We are going
to grow the
first kidney.

Not the first organoid. Not the first prototype. The first kidney that replaces a biological one inside a human body. And we know exactly how to get there.

13Deaths per dayWaiting for a kidney in the US
100K+On the waitlistAverage wait: 3 to 5 years
2M+On dialysis globally$115 billion per year industry
0Synthetic kidneysThat exist for humans today

The Core Thesis

The pieces exist.
Nobody is putting
them together.

The science exists.

50+ labs across 12 countries have solved pieces of the puzzle. Cellular blueprints, scaffold fabrication, vascularization, immune tolerance, clinical monitoring. Every major technical problem has a team working on it right now.

The integration does not.

Not one entity connects all six stacks. Data sits in silos. Labs duplicate each other's work. Progress compounds within institutions, never across the field. The bottleneck is structural, not scientific.

Spark is the bridge.

An AI-powered data mesh that standardizes, synthesizes, and accelerates the entire field. Not a lab. Not a device company. The operating system for synthetic organs.

The Opportunity

$1T

The addressable market when you replace dialysis with a manufacturable kidney. Not the research market. Not the device market. The replacement market for a treatment that does not work.

See the full financial model

How We Win

Not a lab.
The operating system
for the field.

Think of what OpenAI did for AI research. They did not invent the transformer. They unified the research, scaled the compute, attracted the talent, built the infrastructure, and captured the value. That is what Spark does for synthetic organs.

Explore the six stacks
Phase 1

The Data Mesh

Connect 50+ labs. Standardize all six data stacks. Build the federated AI model that learns from every institution without touching their raw data.

Phase 2

The Synthesis Engine

AI that predicts which biological conditions produce functional kidney tissue. The recipe the entire field is missing. Every experiment tightens the model.

Phase 3

The Factory

Automated bioreactor facilities producing patient-specific kidneys at scale. This is where the trillion-dollar valuation lives. 800,000 dialysis patients become the customer base.

Join the Mission

We are looking for
people who believe
this is possible.

Researchers, engineers, investors, and institutions who understand that the bottleneck is not the science. It is the infrastructure. If that is you, we want to talk.

No spam. Updates on launch, partnerships, and open research access.